Revolutionizing AI in drug discovery via innovative molecular representation paradigms
ReMINDER aims to revolutionize drug discovery by developing novel molecular representations for AI, enhancing model capabilities and solving complex chemical challenges.
Projectdetails
Introduction
Artificial intelligence (AI) in the form of deep learning is driving unprecedented progress in numerous fields, e.g., for protein structure prediction and organic reaction planning. In drug discovery and chemical biology, such progress is an evolution rather than a revolution: several tasks still await to be solved by AI, e.g., accurate structure-activity and activity-cliff prediction, and design of structurally innovative chemical matter.
Current Challenges
Increasingly complex deep learning approaches are leading to progressively smaller gains in model capabilities, calling for a revolution in AI for drug discovery. The springboard for this project is a striking observation: while novel deep learning algorithms are in continuous development, the input raw molecular representations they rely on (e.g., SMILES strings and molecular graphs) have not considerably changed in the last four decades, limiting the amount and quality of chemical information learnable by AI.
Potential for Improvement
The potential of capturing more sophisticated chemical information better into a new molecular language is still untapped and bears promise to revolutionize molecular AI. ReMINDER will break with traditional approaches and shift the object of study from increasingly complex algorithms to novel molecular representation paradigms for AI.
Objectives of ReMINDER
ReMINDER will be an agent of change in the molecular AI landscape by developing a new representation framework at the interface between method development and experimental validation. ReMINDER will disrupt the potential of AI to:
- Navigate complex structure-activity landscapes,
- Design innovative bioactive molecules from scratch,
- Leverage binding pocket information for molecule discovery.
Conclusion
By transforming the chemical information captured for AI, we open opportunities to develop more efficient models and solve open scientific challenges. ReMINDER will create the basis for exciting new technology in the field of deep learning for drug discovery and chemistry at large.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.494.006 |
Totale projectbegroting | € 1.494.006 |
Tijdlijn
Startdatum | 1-1-2023 |
Einddatum | 31-12-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- TECHNISCHE UNIVERSITEIT EINDHOVENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistanceAI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance. | ERC Synergy ... | € 10.968.734 | 2025 | Details |
Deep learning of chemical reactionsThis project aims to develop advanced deep learning frameworks for modeling organic and enzymatic reactions to enhance predictions of selectivity and enable sustainable synthesis. | ERC Starting... | € 1.499.285 | 2024 | Details |
Continual and Sequential Learning for Artificial IntelligenceDevelop a Continual and Sequential Learning AI that integrates RL with advanced data gathering to autonomously adapt and explore in dynamic environments for scientific breakthroughs. | ERC Starting... | € 1.259.375 | 2025 | Details |
Automated, miniaturized and accelerated drug discovery: AMADEUSAMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility. | ERC Advanced... | € 3.409.401 | 2024 | Details |
Integrative, AI-aided Inference of Protein Structure and DynamicsThe project aims to develop bAIes, a novel modeling approach combining AI, experimental data, and molecular simulations to enhance protein structure and dynamics characterization, particularly for SARS-CoV-2. | ERC Consolid... | € 2.932.775 | 2023 | Details |
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance
AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.
Deep learning of chemical reactions
This project aims to develop advanced deep learning frameworks for modeling organic and enzymatic reactions to enhance predictions of selectivity and enable sustainable synthesis.
Continual and Sequential Learning for Artificial Intelligence
Develop a Continual and Sequential Learning AI that integrates RL with advanced data gathering to autonomously adapt and explore in dynamic environments for scientific breakthroughs.
Automated, miniaturized and accelerated drug discovery: AMADEUS
AMADEUS is an automated platform for rapid, sustainable drug discovery that synthesizes thousands of small molecules daily, optimizing processes through AI to reduce costs and enhance accessibility.
Integrative, AI-aided Inference of Protein Structure and Dynamics
The project aims to develop bAIes, a novel modeling approach combining AI, experimental data, and molecular simulations to enhance protein structure and dynamics characterization, particularly for SARS-CoV-2.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Drug Discovery IntelligenceHet project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties. | Mkb-innovati... | € 20.000 | 2020 | Details |
QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial IntelligenceThis project aims to revolutionize computational toxicology by developing interpretable quantum mechanics-based descriptors (ESigns) for accurate toxicity predictions across the entire chemical space. | EIC Pathfinder | € 1.994.770 | 2024 | Details |
Reaction robot with intimate photocatalytic and separation functions in a 3-D network driven by artificial intelligenceCATART aims to develop autonomous reaction robots using AI and 3-D quantum dot networks to efficiently mimic natural chemical production, enhancing productivity and sustainability in the chemical industry. | EIC Pathfinder | € 2.871.775 | 2022 | Details |
AI to render the best clinical trial design for a novel RNA therapy.Het ANTENA-project ontwikkelt een AI-platform om de optimale klinische studiepopulatie voor een nieuwe RNA-medicatie te identificeren, met als doel kosten en risico's van klinische proeven te verlagen. | Mkb-innovati... | € 199.700 | 2023 | Details |
Drug Discovery Intelligence
Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.
QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial Intelligence
This project aims to revolutionize computational toxicology by developing interpretable quantum mechanics-based descriptors (ESigns) for accurate toxicity predictions across the entire chemical space.
Reaction robot with intimate photocatalytic and separation functions in a 3-D network driven by artificial intelligence
CATART aims to develop autonomous reaction robots using AI and 3-D quantum dot networks to efficiently mimic natural chemical production, enhancing productivity and sustainability in the chemical industry.
AI to render the best clinical trial design for a novel RNA therapy.
Het ANTENA-project ontwikkelt een AI-platform om de optimale klinische studiepopulatie voor een nieuwe RNA-medicatie te identificeren, met als doel kosten en risico's van klinische proeven te verlagen.